# Diabetes Research Hub — Daily Iteration Report
**Date:** 2026-06-29 (Monday)
**Agent:** automated research agent (state-aware)

## State at start
- Papers: 285 (272 VETTED / 13 FLAGGED / 0 unvetted)
- Research paths: 57 (9 VALIDATED, 3 PARTIALLY, 1 CONTRADICTED, 44 NONE)
- Gaps: 15 | Work queue: 23 items | Run history: 75 runs

## Work performed

### 1. Monday weekly PubMed/web sweep (Step 2 — 7 topic areas)
| Topic | Finding | New PMIDs |
|---|---|---|
| LADA | Case series (PMC12456252) + narrative reviews; no new RCT | 0 |
| Islet transplant 2026 | Tegoprubart UChicago IIT now **10/10 insulin-independent** (mean HbA1c ~5.35%) — still **press/HCPLive only**, no peer-reviewed pub | 0 |
| NLRP3 / diabetic kidney | 2025 kidney review PMID 41357229 (already in corpus); 2026 ferroptosis model (IJMS 27:4257, preclinical) | 0 |
| Verapamil / T1D beta cell | CLVer pediatric RCT positive; Ver-A-T1D adult primary negative — consistent with existing path; new mechanistic PMC12610477 | 0 |
| Dapagliflozin + colchicine | No dedicated diabetes RCT; only empagliflozin+colchicine post-MI trial | 0 |
| Drug repurposing (generic) | Recurring candidates: verapamil, liraglutide, GABA, TUDCA | 0 |
| Oxidative stress combination | Resveratrol meta-analysis (PMC11771208); GLP-1+SGLT2 additive antioxidant capacity | 0 |

**Net: no genuinely new PMIDs.** Top candidate (41357229) already present in corpus.

### 2. Search-queue items confirmed (no status change)
- Tegoprubart islet transplant — still press-only → next 2026-08-02
- Abata ABA-201 TCR-Treg — still pre-first-in-human → next 2026-08-02

### 3. Path validation (Step from queue item #22)
**NLRP3_inflammasome → nephropathy: NONE → PARTIALLY_VALIDATED**
- Strong, consistent mechanistic support across 2024–2026 models (glomerular/tubular injury, CRP–Smad3–NLRP3, ferroptosis) and multiple NLRP3 inhibitors in clinical development.
- **But** no NLRP3-inhibitor RCT has reported a renal primary endpoint in DKD, and MCC950 showed *adverse* renal effects in one interventional model (PMC8777085, counter-signal).
- External PMID: 41357229. Verdict: mechanism validated, clinical efficacy unproven → PARTIALLY.
- Queued `oxidative_stress → T2D` for next-run validation (fresh evidence on hand).

### 4. Credibility sweep (Step 4) — **CLEAN**
- No fabricated PMIDs (>42000000) in any script.
- No "zero SAEs" / "zero rejection". "achieves" hits were mechanism/cost/ML-metric language (TTP399 tissue selectivity, cost-effectiveness ratio, macro-AUC) + the verifier script itself — not overstated clinical claims.

### 5. Pipeline rebuild (Step 5) — **41/41 [OK]**
`run_quality_improvements.py` completed; all builds, PMID verification, citation validation, and dashboard post-processing succeeded.

## State at end
- Paths: 9 VALIDATED, **4 PARTIALLY**, 1 CONTRADICTED, **43 NONE**
- Run history: 76 runs

## Blocker (Step 6 — unresolved, requires user)
Git commit/push remains **blocked in the sandbox**: OneDrive denies `unlink`, so git cannot clear `.git/index.lock`; repo is ahead of origin with uncommitted working-tree changes. **User fix (PowerShell in the OneDrive copy):**
`del .git\index.lock` → optionally `Get-ChildItem .git\index.* -Exclude index | Remove-Item -Force` → `git add -A; git commit -m "sync 2026-06-29 daily iteration"; git push`
